Scientific research ROS 1 Fusion (English)

preview_player
Показать описание
A collaboration between Merels Wereld Foundation, University Medical Center Groningen, Hanzehogeschool Groningen and Indiveo.
  1. Indiveo
Рекомендации по теме
Scientific research ROS 0:02:58

Scientific research ROS 1 Fusion (English)

Scientific research ROS 0:03:23

Scientific research ROS 1 Fusion (German)

Scientific research ROS 0:03:18

Scientific research ROS 1 Fusion (Spanish)

ROS-1 Rearrangements: What 0:01:53

ROS-1 Rearrangements: What Are They?

Dr. Riess on 0:01:51

Dr. Riess on ROS1 Fusions in Lung Cancer

ROS-1 Lung Cancer 2:00:53

ROS-1 Lung Cancer Patients (English version)

EML4/ALK and ROS-1: 0:21:51

EML4/ALK and ROS-1: How do we sequence therapies

2020 TTF ALK 0:25:07

2020 TTF ALK SESSION - LIN - TKIs for ROS1

ROS1 Biomarker Lung 0:02:20

ROS1 Biomarker Lung Cancer: What Does That Mean?

Crizotinib treatment in 0:02:45

Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion – Video abstract ID 136297

The therapeutic implications 0:26:24

The therapeutic implications of EML4/ALK, ROS-1 and other actionable biomarkers

The therapeutic implications 0:22:51

The therapeutic implications of EML4/ALK, ROS-1 and other actionable biomarkers

ROS - Dr 0:11:47

ROS - Dr Sunil Pasricha - Interpretation Of ROS 1 Rearrangement In NSCLC

Lysa Supports ROS1+ 0:00:28

Lysa Supports ROS1+ Cancer Research

ROS - Dr 0:13:55

ROS - Dr Venkata Pradeep Babu Selection Of 1st Line Therapy For ROS 1 Rearrangement IN NSCLC

FLOW CYTOMETRY in 0:01:34

FLOW CYTOMETRY in 1 minute

ROS1 Treatment Options: 0:07:07

ROS1 Treatment Options: Crizotinib and Entrectinib - 2022 Program: Targeted Therapies Forum

Multiple Therapies Show 0:01:55

Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions

Side Effects of 0:04:10

Side Effects of ROS1-TKIs - 2022 Program: Targeted Therapies Forum

Expanded Clinical Research 0:35:27

Expanded Clinical Research Opportunities for Crizotinib Identified

Verification of an 0:02:58

Verification of an Ion AmpliSeq™ RNA Fusion Lung Cancer Research Panel: ASHG 2014 Poster

Extreme Rare Mutations 0:18:41

Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunities

Comprehensive NTRK Fusion 0:55:52

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion ..

Targeted Therapies Show 0:01:27

Targeted Therapies Show Activity in ROS1 Fusion-Positive Lung Cancer

visit shbcf.ru